Antifibrotic Therapy Decision-Making in Pulmonary Fibrosis
NCT07722507 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40
Last updated 2026-07-23
Summary
This study will explore how adults in Japan with pulmonary fibrosis decide whether to continue or discontinue antifibrotic therapy after experiencing antifibrotic therapy-related adverse events.
Conditions
Interventions
- DRUG
-
Antifibrotic therapy
As per product label prescribed by treating physician
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-08-01
- Primary Completion
- 2027-05-31
- Completion
- 2027-05-31
- FDA Drug
- Yes
Countries
- Japan
Study Locations
More Related Trials
-
Pulmonary Fibrosis and Telomerase Mutation Study
NCT01501578 ·Status: COMPLETED
-
Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases
NCT00005317 ·Status: COMPLETED
-
Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00373841 ·Status: RECRUITING
-
Analysis of Specimens From Individuals With Pulmonary Fibrosis
NCT00084305 ·Status: ACTIVE_NOT_RECRUITING
-
Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis
NCT02151435 ·Status: COMPLETED
-
Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
NCT00212511 ·Status: WITHDRAWN
-
Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF)
NCT01071707 ·Status: COMPLETED
-
Idiopathic Pulmonary Fibrosis: a Case-control Study
NCT00005295 ·Status: TERMINATED
-
Optimising Screening for Early Disease Detection in Familial Pulmonary Fibrosis
NCT05367349 ·Status: UNKNOWN
-
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
NCT00162760 ·Status: COMPLETED ·Phase: PHASE2
-
Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers
NCT02834104 ·Status: COMPLETED ·Phase: NA
-
PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis
NCT06855329 ·Status: RECRUITING
-
Clinical Genetics and Screening for Idiopathic Pulmonary Fibrosis
NCT06521125 ·Status: NOT_YET_RECRUITING
-
Anti-Inflammatory Pulmonal Therapy of CF-Patients With Amitriptyline and Placebo
NCT00515229 ·Status: COMPLETED ·Phase: PHASE2
-
Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder
NCT00722254 ·Status: TERMINATED
-
CAR-DC for End-Stage IPF
NCT07329959 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
NCT00850551 ·Status: COMPLETED ·Phase: NA
-
Scleroderma Lung Disease
NCT00004563 ·Status: COMPLETED ·Phase: PHASE3
-
Metabolomic Biomarkers Evaluation in Pulmonary Fibrosis
NCT06974799 ·Status: COMPLETED
-
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome
NCT00467831 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF)
NCT00258544 ·Status: ACTIVE_NOT_RECRUITING
-
Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial
NCT03007134 ·Status: COMPLETED
-
Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients
NCT05899556 ·Status: NOT_YET_RECRUITING
-
Early Discontinuation of Steroid Treatment in Negative FDG-PET/CT Patients With Idiopathic Retroperitoneal Fibrosis
NCT05428826 ·Status: RECRUITING ·Phase: PHASE4
-
Diagnosis and Treatment of Patients With Cystic Fibrosis
NCT00001223 ·Status: TERMINATED